2. For more than 5 years, the International Market Analysis Research and Consulting Group has
been a leading advisor on management strategy and market research worldwide. We partner
with clients in all sectors and regions to identify their highest-value opportunities, address their
most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing
methods are at the top of the company's expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our
clients achieve unmatchable competitive advantage, build more proficient organizations, and
secure lasting results.

3. & '
! "
" # $%&
' () $*& +,- *.$ /
$001 " 20& *% 200
/ 3 #
4 5 $02%
"/ ) ' 6 (!"#"$!"#%78
9
9
#
'
• : " ! " 9
# # +,- $ ; < $02%
• " $001 ! " +,- =%> /
< $;&
• ( " "
=%& $001
• : "? " $020 #
# +,- 2>$ /
• ' " () =2& $00% $001 +,-
$;% / $001
• 9 " @
7 1$& $001 " @! ! 7
>2&
!"#"$!"#%

4. & *+ ,- & *
• !
• :
• :
• ! "
( "
(
( 3
,
: "? "
<
(A 2
! "
• "
. , / - & *+ & & , *
• $00% $001
• $00% $001 ! "
• $00% $001 ! " :
• $00% $001 ! " :
• $00% $001 "
• $00% $001 B "
0 12 3 -
• 3 C
• C
• C
• ,3 < C
• ,3 < ! " C
• ,3 < " C
• C
• # C
• # # C
• # C
• C
) !"#"$!"#%

5. Table of Contents
1. Executive Summary............................................................................................................. 12
2. Diabetes Disease Overview ................................................................................................. 14
3. The Chinese Diabetes Market: Why is it so Lucrative? ................................................. 21
4. Drivers of Diabetes in China .............................................................................................. 28
!
"
5. The Chinese Diabetes Epidemiology .................................................................................. 32
!
" # $ %
!
6. The Chinese Diabetes Market ............................................................................................ 41
# !! $ !!%&
# !! $ !!%&
# ! !$ ! &
7. The Chinese Non-Insulin Anti-diabetics Market.............................................................. 45
' # !! $ !!%&
% !"#"$!"#%

6. ' # !! $ !!%&
' # ! !$ ! & '
' # !! $ ! &
& " $' (# ) ' *
' ()*+, )+-. # !! $ !!%&
' /01+,2,23+ (-.45(1+
' 6()+ /7 +8 9(8+)4
' /),7/92/ /7 +8 9(8+)4
' ()*+, /)+5(4,4 # ! !$ ! &
& #
' ()*+, )+-. # !! $ !!%&
' /01+,2,23+ (-.45(1+
' 6()+ /7 +8 9(8+)4
' /),7/92/ /7 +8 9(8+)4 '
' ()*+, /)+5(4,4 # ! !$ ! &
& # + ,
' ()*+, )+-. # !! $ !!%& %
' /01+,2,23+ (-.45(1+ !
' 6()+ /7 +8 9(8+)4 !
' /),7/92/ /7 +8 9(8+)4
' ()*+, /)+5(4,4 # ! !$ ! &
& $'
' ()*+, )+-. # !! $ !!%&
' /01+,2,23+ (-.45(1+
' 6()+ /7 +8 9(8+)4
' /),7/92/ /7 +8 9(8+)4
' ()*+, /)+5(4,4 # ! !$ ! & '
& - &
' ()*+, )+-. # !! $ !!%&
' /01+,2,23+ (-.45(1+
' 6()+ /7 +8 9(8+)4
' /),7/92/ /7 +8 9(8+)4 %
' ()*+, /)+5(4,4 # ! !$ ! & '!
& $$(). ) ' &
' /01+,2,23+ (-.45(1+ '
' 6()+ /)+5(4, 7/) +8 9(8+)4 '
' /),7/92/ /7 +8 9(8+)4 '
' ()*+, /)+5(4,4 # ! !$ ! & '
& & # $( " &
' ' /01+,2,23+ (-.45(1+ '
4 !"#"$!"#%

7. ' ' 6()+ /)+5(4, 7/) +8 9(8+)4 '
' ' /),7/92/ /7 +8 9(8+)4 ''
' ' ()*+, /)+5(4,4 # ! !$ ! & '
& % " ' / &%
' ()*+, )+-. # !! $ !!%& '
' /01+,2,23+ (-.45(1+ '%
' 6()+ /7 +8 9(8+)4 '%
' /),7/92/ /7 +8 9(8+)4 !
' ()*+, /)+5(4,4 # ! !$ ! &
8. The Chinese Insulin Market ............................................................................................... 82
# !! $ !!%&
# !! $ !!%&
'
% ' 0 %&
% ) 1 %,
# !! $ ! !& %
9. Road Blocks .......................................................................................................................... 93
% : %
% ; %
% < %
% %
5 !"#"$!"#%

8. List of Figures
Figure 2:1: The impact of Diabetes in the Human Body ............................................................................. 14
Figure 2:2: Diabetes Complications ............................................................................................................ 20
Figure 3:1: China - Personal Disposable Income (in US$ per Head), 2005-2015 ...................................... 23
Figure 3:2: China - Breakup of Consumer Expenditure (%), 2007, 2010 & 2015....................................... 24
Figure 3:3: China: Tapped and Untapped Diabetes Market, (in Million US$), 2010................................... 26
Figure 4:1: China: Breakup of Total Population by Age Groups (0-14, 15-64 & 65-99), (In Million), 2005,
2010, 2015, 2020, 2025 .............................................................................................................................. 28
Figure 4:2: China: Breakup of Total Population by Age Groups (0-14, 15-64 & 65-99), (in %),................. 29
Figure 4:3 : China: Diabetes Prevalence Forecast by age groups, (in %),................................................. 29
Figure 4:4: China: Overweight & Obese Patient Forecast, (in Million), 2005, 2010, 2015, 2020 & 2025... 30
Figure 4:5: Body Mass Index and Relative risk of Type-2 Diabetes ........................................................... 30
Figure 4:6: China: Prevalence of Diabetes by Region (%), 2002 ............................................................... 31
Figure 5:1: China: Total Number of Diabetes Patients* (in Million), 2005 & 2010 ...................................... 32
Figure 5:2: China: Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 &
2030 ............................................................................................................................................................ 33
Figure 5:3: China (Urban & Rural): Total Number of Diabetes Patients* (in Million), 2005 & 2010 ........... 34
Figure 5:4: China (Urban & Rural): Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015,
2020, 2025 & 2030 ...................................................................................................................................... 34
Figure 5:5: China: Breakup of Diabetes Patients* by Urban/Rural Regions, (in %), 2010 & 2030............. 35
Figure 5:6: China (Male & Female): Total Number of Diabetes Patients* (in Million), 2005 & 2010 .......... 36
Figure 5:7: China (Male & Female): Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015,
2020, 2025 & 2030 ...................................................................................................................................... 36
Figure 5:8: China: Breakup of Diabetes Patients by Sex, (in %), 2010 & 2030......................................... 36
Figure 5:9: China: Total Number of Diabetes Patients* by Age Group (20-39), (40-59) & (60-79) ............ 38
Figure 5:10: China: Total Number of Diabetes Patients* by Age Group (20-39), (40-59) & (60-79) .......... 39
Figure 5:11 : China: Breakup of Diabetes Patients by Age Group, (in %), 2010 & 2030 ........................... 39
Figure 5:12: China: Total Diabetes Diagnosed & Drug Treated Population*, 2005, 2010 & 2015 ............. 40
Figure 6:1: China: Diabetes Market, (in Million US$), 2005-2009 .............................................................. 41
Figure 6:2: China: Diabetes Market, Share of Non-Insulin Anti-diabetics and Insulin (in %), .................... 41
Figure 6:3: China: Diabetes Market, (in Million US$), 2010-2015 .............................................................. 43
Figure 6:4: China: Diabetes Market Forecast, Share of Non-Insulin Anti-diabetics and Insulin (in %), ..... 43
Figure 6:5: China: Contribution of Non-Insulin Anti-diabetics & Insulin towards Total Growth,.................. 44
Figure 7:1: China: Non-Insulin Anti-diabetics Sales, (in Million US$), 2005-2009...................................... 45
Figure 7:2: China: Non-Insulin Anti-diabetics Market, Value Market Shares of Key Players (in %), .......... 46
Figure 7:3: China: Non-Insulin Anti-diabetics Sales Forecast, (in Million US$), 2010-2015 ...................... 47
!"#"$!"#%

9. Figure 7:5: China: Non-Insulin Anti-diabetics Market Forecast, Value Shares of Key Classes (in %), 2015
.................................................................................................................................................................... 49
Figure 7:6: China: Alpha-Glycosidase Inhibitor Anti-diabetics Sales, (in Million US$), 2005-2009 ............ 51
Figure 7:7: China: Alpha-Glycosidase Inhibitor Market, Value Market Shares of Key Players (in %), ....... 52
Figure 7:8: China: Alpha Glycosidase inhibitor Anti-diabetics Sales Forecast, (in Million US$), ............... 55
Figure 7:9: China: Glinide Anti-diabetics Sales, (in Million US$), 2005-2009............................................. 56
Figure 7:10: China: Glinide Anti-diabetics Market, Value Market Shares of Key Players (in %), ............... 57
Figure 7:11: China: Glinide Anti-diabetics Sales Forecast, (in Million US$), 2010-2015 ........................... 58
Figure 7:12: China: Glitazone Anti-diabetics Sales, (in Million US$), 2005-2009....................................... 59
Figure 7:13: China: Glitazone Anti-diabetics Market, Value Market Shares of Key Players (in %), ........... 60
Figure 7:14: China: Glitazone Anti-diabetics Sales Forecast, (in Million US$), 2010-2015 ....................... 63
Figure 7:15: China: Sulphonylurea Anti-diabetics Sales, (in Million US$), 2005-2009 ............................... 64
Figure 7:16: China: Sulphonylurea Anti-diabetes, Value Market Shares of Key Players (in %),................ 65
Figure 7:17: China: Sulphonylurea Anti-diabetics Sales Forecast, (in Million US$), 2010-2015................ 67
Figure 7:18: China: Biguanide Anti-diabetics Sales, (in Million US$), 2005-2009 ...................................... 68
Figure 7:19: China: Biguanide Anti-diabetics Market, Value Market Shares of Key Players (in %), .......... 69
Figure 7:20: China: Biguanide Anti-diabetics Sales Forecast, (in Million US$), 2010-2015 ....................... 71
Figure 7:21: China: DPP-IV Inhibitors, Value Market Share Forecast of Key Players (in %), .................... 73
Figure 7:22: China: DPP-IV Inhibitor Anti-diabetics Sales Forecast, (in Million US$), 2010-2015 ............. 75
Figure 7:23: China: Glp-1 Agonist Anti-diabetics Market, Value Market Shares of Key Players................ 76
Figure 7:24: China: Glp-1 Agonist Anti-diabetics Sales Forecast, (in Million US$), 2010-2015 ................. 78
Figure 7:25: China: All other Classes Anti-diabetics Sales, (in Million US$), 2005-2009 ........................... 79
Figure 7:26: China: All Other Classes Anti-diabetics Market, Value Market Shares of Key Players.......... 80
Figure 7:27: China: All other Anti-diabetics Classes Sales Forecast, (in Million US$), 2010-2015............ 81
Figure 8:1: China: Insulin Sales, (in Million US$), 2005-2009 .................................................................... 82
Figure 8:2: China: Insulin Market, Value Market Shares of Key Molecules (in %), .................................... 85
Figure 8:3: China: Insulin Market, Value Market Shares by Mode of Action (in %), 2009 .......................... 86
Figure 8:4: China: Insulin Market, Value Market Shares of Key Players (in %), 2005-2009 ...................... 88
Figure 8:5: China: Insulin Sales Forecast, (in Million US$), 2010-2015 ..................................................... 92
Figure: 9:1: Average per patient spending on Diabetes Drugs by Major Developed and Emerging Markets,
2010 ............................................................................................................................................................ 93
!"#"$!"#%

10. List of Tables
Table 2-1: Diagnosis of Diabetes ................................................................................................................ 16
Table 3-1: Statistics of Top Emerging and Developed Diabetes Markets, 2010 & 2030 ............................ 21
Table 3-2: Statistics of Top Emerging and Developed Diabetes Markets 2009 ......................................... 22
Table 3-3: Drugs Expected to be Launched in the Chinese Diabetes Market, 2010-2015 ........................ 27
Table 5-1: China: Total Diabetes Diagnosed & Drug Treated Population, 2005, 2010 & 2015 ................. 40
Table 7-1: China: Non-Insulin Anti-diabetics Market, Sales of Key Players (in 000’ US$), ........................ 46
Table 7-2: China: Non-Insulin Anti-diabetics Market, Sales of Key Classes (in 000’ US$), ....................... 48
Table 7-4: China: Non-Insulin Anti-diabetics Market Forecasts, Sales of Key Classes (in 000’ US$), ...... 48
Table 7-5: China: Non-Insulin Anti-diabetics Market Forecasts, Value Shares of Key Classes (in %), ..... 49
Table 7-6: China: Alpha-Glycosidase Inhibitor Market, Sales of Key Players (in 000’ US$), .................... 52
Table 7-7: China: Bayer’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$), ............................... 53
Table 7-8: China: Hangzhou’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$), ........................ 53
Table 7-9: China: Sc.lz.Baoguang’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$), ............... 54
Table 7-10: China: Takeda’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$), .......................... 54
Table 7-11: China: Jiangsu’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$), .......................... 54
Table 7-12: China: Glinide Anti-diabetics Market, Sales of Key Players (in 000’ US$), 2005-2009........... 56
Table 7-13: China: Novo Nordisk Glinide Portfolio Sales (in 000’ US$), 2005-2009 .................................. 57
Table 7-14: China: JS.L.Y.G. Glinide Portfolio Sales (in 000’ US$), 2005-2009 ........................................ 57
Table 7-15: China: Novartis’s Glinide Portfolio Sales (in 000’ US$), 2005-2009........................................ 58
Table 7-16: China: Js.Yangzijiang Glinide Portfolio Sales (in 000’ US$), 2005-2009 ................................ 58
Table 7-17: China: Glitazone Anti-diabetics Market, Sales of Key Players (in 000’ US$), ......................... 60
Table 7-18: China: GlaxoSmithKline’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009 ...................... 61
Table 7-19: China: Sichuan Taiji Ph’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009 ....................... 61
Table 7-20: China: Beijing Taiyang’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009 ........................ 61
Table 7-21: China: JS.L.Y.G.’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009 ................................. 61
Table 7-22: China: Hangzhou’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009 ................................ 62
Table 7-23: China: Sulphonylurea Anti-diabetics Market, Sales of Key Players (in 000’ US$), ................. 64
Table 7-24: China: Servier Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$), ............................ 66
Table 7-25: China: Sanofi Aventis Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$), ................ 66
Table 7-26: China: Shuanghe Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),....................... 66
Table 7-27: China: Pfizer’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$), ........................... 66
Table 7-28: China: Shanghai Fosun’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$), .......... 67
Table 7-29: China: Biguanide Anti-diabetics Market, Sales of Key Players (in 000’ US$), 2005-2009 ...... 69
Table 7-30: China: Bristol-Myers Biguanide Portfolio Sales (in 000’ US$), 2005-2009 ............................. 70
Table 7-31: China: Bj.Liling Hengtai Biguanide Portfolio Sales (in 000’ US$), ........................................... 70
Table 7-32: China: C.T-Tianqing Biguanide Portfolio Sales (in 000’ US$), ................................................ 70
#" !"#"$!"#%

11. Table 7-33: China: Guizhou Biguanide Portfolio Sales (in 000’ US$), ....................................................... 70
Table 7-34: China DPP-IV Inhibitors, Sales Forecast of Key Players (in 000’ US$), 2010 & 2015............ 72
Table 7-35: China: MSD’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2010 & 2015 ........................... 73
Table 7-36: China: BMS /AstraZeneca DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2015.................... 73
Table 7-37: China: Boehringer Ingelheim’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2015 ............. 74
Table 7-38: China: Takeda’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2015 ................................... 74
Table 7-39: China: Novartis’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2015 .................................. 74
Table 7-40: China: Glp-1 Agonist Anti-diabetics Market, Sales Forecast of Key Players (in 000’ US$),
2008 & 2009 ................................................................................................................................................ 76
Table 7-41: China: Lilly’s Glp-1 Agonist Portfolio Sales (in 000’ US$) ....................................................... 77
Table 7-42: China: Novo Nordisk’s Glp-1 Agonist Portfolio Sales (in 000’ US$), ....................................... 77
Table 7-43: China: Ipsen/Roches’s Glp-1 Agonist Portfolio Sales (in 000’ US$) ....................................... 77
Table 7-44: China: Sanofi Aventis’s Glp-1 Agonist Portfolio Sales (in 000’ US$) ...................................... 77
Table 7-45: China: All Other Classes Anti-diabetics Market, Sales of Key Players (in 000’ US$), ............ 79
Table 7-46: China: Js.Nj.Hailing Pharma’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
2005-2009 ................................................................................................................................................... 80
Table 7-47: China: Sh.Xiandai’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), ............... 80
Table 7-48: China: YabaoTaiyuan All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), ............ 81
Table 7-49: China: C.T-Tianqing All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), .............. 81
Table 7-50: China: Shanghai Fosun All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), ......... 81
Table 8-1: China: Insulin Value Shares by Molecule (in 000’ US$), 2005-2009......................................... 83
Table 8-2: China: Insulin Value Shares by Molecule (in %), 2005-2009 .................................................... 84
Table 8-3: China: Insulin Value Sales by Mode of Action (in 000’US$), 2005-2009 .................................. 85
Table 8-4: China: Insulin Value Shares by Mode of Action (in %), 2005-2009........................................... 86
Table 8-5: China: Insulin Market, Sales of Key Players (in 000’ US$), 2005-2009 .................................... 87
Table 8-6: China: Novo Nordisk’s Insulin Portfolio Sales (in 000’ US$), 2005-2009 .................................. 89
Table 8-7: China: Lilly’s Insulin Portfolio Sales (in 000’ US$), 2005-2009 ................................................. 89
Table 8-8: China: Sanofi Aventis’s Insulin Portfolio Sales (in 000’ US$), 2005-2009 ................................ 89
Table 8-9: China: Tonghua Dongbao’s Insulin Portfolio Sales (in 000’ US$), 2005-2009 .......................... 91
Table 8-10: China: Bj Ganli Pharma’s Insulin Portfolio Sales (in 000’ US$), 2005-2009 ........................... 91
## !"#"$!"#%

12. Prices and Order Information
Electronic Access Electronic Access CD-ROM Mail Delivery Hard Copy Mail Delivery
(Single User License) (Multi User License) (Single User License) (Single User License)
US$ 800 US$ 2400 US$ 1400 US$ 1400
For more information visit: http://www.imarcgroup.com/china-diabetes-market-report-and-outlook-
2010-2015/
To buy the complete report or to get a free sample:
Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America)
Email:sales@imarcgroup.com